Conatus Pharmaceuticals is a San Diego biotech company focused on developing therapies for liver disease and cancer. Its lead development candidate is CTS-1027, a clinical-stage drug licensed from F. Hoffmann-LaRoche Ltd that is the subject of multiple Phase 2 trials in hepatitis C patients. The company recently obtained a $7.5 million follow-on investment from MPM Capital. That investment brings total invested capital to $32.5 million. Conatus said it will use the funds to advance clinical development of CTS-1027 and to proceed with trials started in January. The financing also supports evaluation of compounds the company acquired last year with Idun Pharmaceuticals. Conatus Pharmaceuticals is a San Diego biopharmaceutical company focused on developing human therapeutics for liver disease and oncology. The company closed a $20M Series B financing that will remain open while other potential investors conclude diligence. Proceeds will be used to advance the clinical development of CTS-1027, a clinical-stage drug candidate licensed from F. Hoffman-La Roche, Ltd. CTS-1027 is the subject of multiple Phase 2 clinical trials in HCV-infected patients. The round was led by new investor AgeChem Venture Fund with participation from Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners and Roche Venture Fund. Louis Lacasse from AgeChem will join the company’s board alongside CEO Steven J. Mento and other existing board members. Conatus was founded in July 2005 by the executive management team of Idun Pharmaceuticals following Idun’s sale to Pfizer. Conatus Pharmaceuticals is a San Diego developer focused on drugs for inflammation and liver disease. Its lead compound is CTS-1027, which the company licensed from Roche last November. The funding will support mid-stage clinical trials of CTS-1027. The first trial, in hepatitis C patients, is expected to begin by the end of this year. Conatus was founded in mid-2005 by former executives of Idun Pharmaceuticals after Pfizer acquired that company. The company completed a financing that increases resources available to advance its clinical program.

Total raised

$50M

Funding rounds

3

Latest round

Series B

Latest activity

Apr 2011